-
Something wrong with this record ?
Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1
P. Šimon, O. Baszczyňski, D. Šaman, G. Stepan, E. Hu, EB. Lansdon, P. Jansa, Z. Janeba,
Language English Country France
Document type Journal Article
- MeSH
- HIV Reverse Transcriptase antagonists & inhibitors chemistry metabolism MeSH
- HIV-1 drug effects enzymology MeSH
- Reverse Transcriptase Inhibitors chemistry metabolism pharmacology MeSH
- Protein Conformation MeSH
- Pyrimidines chemistry metabolism pharmacology MeSH
- Drug Design * MeSH
- Molecular Docking Simulation MeSH
- Publication type
- Journal Article MeSH
To elucidate the structure-geometry-activity relationship in diarylpyrimidine family (DAPYs) containing carbonyl linker between the central pyrimidine core and phenyl type B-arm, a series of (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones was designed, prepared and tested for their anti-HIV-1 activity. The carbonyl linker bearing B phenyl arm was successfully attached at both C-2 and C-4 positions of the central pyrimidine ring using a new synthetic approach. Further modifications of target compounds are present at C-5 position of the pyrimidine ring. In vitro anti-HIV-1 activity study performed on a series of 22 compounds confirmed the crucial importance of both conformational rigidity between phenyl B arm and the pyrimidine core linked through the carbonyl bridge, as well as presence of fluoro substituents in ortho-positions of phenyl B moiety. The most potent derivative of the series, compound 17, having almost perpendicular angle within the two planes made from the B aromatic arm and the pyrimidine ring, exhibited low nanomolar anti-HIV-1 activity (EC50 = 4 nM) with no significant toxicity (CC50 > 57.1 μM).
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17013733
- 003
- CZ-PrNML
- 005
- 20170418110732.0
- 007
- ta
- 008
- 170413s2016 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ejmech.2016.06.026 $2 doi
- 035 __
- $a (PubMed)27371922
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Šimon, Petr $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague-6 CZ-16610, Czech Republic.
- 245 10
- $a Novel (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones with restricted conformation as potent non-nucleoside reverse transcriptase inhibitors against HIV-1 / $c P. Šimon, O. Baszczyňski, D. Šaman, G. Stepan, E. Hu, EB. Lansdon, P. Jansa, Z. Janeba,
- 520 9_
- $a To elucidate the structure-geometry-activity relationship in diarylpyrimidine family (DAPYs) containing carbonyl linker between the central pyrimidine core and phenyl type B-arm, a series of (2,6-difluorophenyl)(2-(phenylamino)pyrimidin-4-yl)methanones was designed, prepared and tested for their anti-HIV-1 activity. The carbonyl linker bearing B phenyl arm was successfully attached at both C-2 and C-4 positions of the central pyrimidine ring using a new synthetic approach. Further modifications of target compounds are present at C-5 position of the pyrimidine ring. In vitro anti-HIV-1 activity study performed on a series of 22 compounds confirmed the crucial importance of both conformational rigidity between phenyl B arm and the pyrimidine core linked through the carbonyl bridge, as well as presence of fluoro substituents in ortho-positions of phenyl B moiety. The most potent derivative of the series, compound 17, having almost perpendicular angle within the two planes made from the B aromatic arm and the pyrimidine ring, exhibited low nanomolar anti-HIV-1 activity (EC50 = 4 nM) with no significant toxicity (CC50 > 57.1 μM).
- 650 12
- $a racionální návrh léčiv $7 D015195
- 650 _2
- $a HIV reverzní transkriptasa $x antagonisté a inhibitory $x chemie $x metabolismus $7 D054303
- 650 _2
- $a HIV-1 $x účinky léků $x enzymologie $7 D015497
- 650 _2
- $a simulace molekulového dockingu $7 D062105
- 650 _2
- $a konformace proteinů $7 D011487
- 650 _2
- $a pyrimidiny $x chemie $x metabolismus $x farmakologie $7 D011743
- 650 _2
- $a inhibitory reverzní transkriptasy $x chemie $x metabolismus $x farmakologie $7 D018894
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Baszczyňski, Ondřej $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague-6 CZ-16610, Czech Republic.
- 700 1_
- $a Šaman, David $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague-6 CZ-16610, Czech Republic.
- 700 1_
- $a Stepan, George $u Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
- 700 1_
- $a Hu, Eric $u Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
- 700 1_
- $a Lansdon, Eric B $u Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
- 700 1_
- $a Jansa, Petr $u Gilead Sciences Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
- 700 1_
- $a Janeba, Zlatko $u Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Flemingovo nám. 2, Prague-6 CZ-16610, Czech Republic. Electronic address: janeba@uochb.cas.cz.
- 773 0_
- $w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 122, č. - (2016), s. 185-95
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27371922 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170413 $b ABA008
- 991 __
- $a 20170418111040 $b ABA008
- 999 __
- $a ok $b bmc $g 1200198 $s 974511
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 122 $c - $d 185-95 $e 20160617 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
- LZP __
- $a Pubmed-20170413